CD79B mutation
|
Lymphoma
|
CD79B mutation
|
Lymphoma
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
JNJ-67856633 Sensitive: D – Preclinical
|
JNJ-67856633 Sensitive: D – Preclinical
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
venetoclax + ibrutinib Sensitive: D – Preclinical
|
venetoclax + ibrutinib Sensitive: D – Preclinical
|